| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Denmark | 130 | 2022 | 2654 | 4.11 | Why? |
| Atrial Fibrillation | 38 | 2021 | 2320 | 2.97 | Why? |
| Registries | 86 | 2021 | 12327 | 1.80 | Why? |
| Out-of-Hospital Cardiac Arrest | 16 | 2020 | 1047 | 1.63 | Why? |
| Electric Countershock | 8 | 2019 | 284 | 1.15 | Why? |
| Warfarin | 6 | 2019 | 402 | 1.05 | Why? |
| Anti-Inflammatory Agents, Non-Steroidal | 5 | 2019 | 1454 | 0.99 | Why? |
| Dermatitis, Atopic | 10 | 2018 | 714 | 0.97 | Why? |
| Hemorrhage | 11 | 2019 | 3013 | 0.96 | Why? |
| Anticoagulants | 22 | 2019 | 9563 | 0.89 | Why? |
| Myocardial Infarction | 18 | 2021 | 3361 | 0.89 | Why? |
| Endocarditis | 7 | 2019 | 368 | 0.86 | Why? |
| Thromboembolism | 10 | 2020 | 2101 | 0.84 | Why? |
| Heart Failure | 21 | 2021 | 6638 | 0.80 | Why? |
| Lupus Erythematosus, Cutaneous | 2 | 2018 | 104 | 0.79 | Why? |
| Defibrillators, Implantable | 8 | 2019 | 624 | 0.73 | Why? |
| Adrenergic beta-Antagonists | 8 | 2019 | 465 | 0.72 | Why? |
| Thiazolidinediones | 1 | 2017 | 70 | 0.68 | Why? |
| Incidence | 56 | 2021 | 25622 | 0.65 | Why? |
| Cardiovascular Diseases | 14 | 2022 | 11497 | 0.64 | Why? |
| Cardiopulmonary Resuscitation | 10 | 2019 | 1876 | 0.62 | Why? |
| Stroke | 20 | 2021 | 8839 | 0.61 | Why? |
| Risk Factors | 84 | 2021 | 71621 | 0.59 | Why? |
| Parent-Child Relations | 1 | 2019 | 384 | 0.59 | Why? |
| Psoriasis | 9 | 2018 | 1739 | 0.57 | Why? |
| Defibrillators | 4 | 2019 | 144 | 0.57 | Why? |
| Rivaroxaban | 4 | 2019 | 467 | 0.54 | Why? |
| Family Health | 1 | 2019 | 731 | 0.53 | Why? |
| Death, Sudden, Cardiac | 5 | 2019 | 522 | 0.53 | Why? |
| Pacemaker, Artificial | 4 | 2019 | 431 | 0.52 | Why? |
| Vitamin K | 8 | 2019 | 263 | 0.51 | Why? |
| Heart Valve Prosthesis Implantation | 5 | 2019 | 552 | 0.51 | Why? |
| Heart Defects, Congenital | 2 | 2019 | 933 | 0.49 | Why? |
| Myocardial Ischemia | 5 | 2021 | 781 | 0.49 | Why? |
| Population Surveillance | 7 | 2019 | 4967 | 0.48 | Why? |
| Ibuprofen | 3 | 2020 | 156 | 0.47 | Why? |
| Proportional Hazards Models | 25 | 2020 | 6543 | 0.47 | Why? |
| Aged | 114 | 2021 | 215776 | 0.46 | Why? |
| Coronary Artery Bypass | 4 | 2019 | 629 | 0.45 | Why? |
| Pulmonary Embolism | 4 | 2021 | 4775 | 0.45 | Why? |
| Brain Ischemia | 5 | 2021 | 2813 | 0.45 | Why? |
| Arthritis, Psoriatic | 4 | 2018 | 625 | 0.44 | Why? |
| Syncope | 3 | 2018 | 238 | 0.42 | Why? |
| Male | 136 | 2021 | 367725 | 0.42 | Why? |
| Female | 138 | 2021 | 380317 | 0.41 | Why? |
| Middle Aged | 113 | 2021 | 270681 | 0.41 | Why? |
| Risk Assessment | 36 | 2021 | 25439 | 0.41 | Why? |
| Sick Leave | 3 | 2017 | 318 | 0.40 | Why? |
| Endocarditis, Bacterial | 3 | 2019 | 344 | 0.38 | Why? |
| Echocardiography, Doppler | 3 | 2020 | 269 | 0.37 | Why? |
| Hypoxia, Brain | 3 | 2019 | 92 | 0.36 | Why? |
| Case-Control Studies | 23 | 2021 | 17671 | 0.36 | Why? |
| Time Factors | 37 | 2020 | 31397 | 0.36 | Why? |
| Drug Utilization | 3 | 2019 | 619 | 0.36 | Why? |
| Cohort Studies | 35 | 2022 | 36005 | 0.35 | Why? |
| Renal Dialysis | 4 | 2019 | 4358 | 0.35 | Why? |
| Follow-Up Studies | 26 | 2021 | 17020 | 0.35 | Why? |
| Long Term Adverse Effects | 2 | 2019 | 119 | 0.35 | Why? |
| Aged, 80 and over | 50 | 2021 | 88759 | 0.34 | Why? |
| Diclofenac | 2 | 2017 | 27 | 0.34 | Why? |
| Fathers | 2 | 2018 | 114 | 0.33 | Why? |
| Return to Work | 3 | 2017 | 579 | 0.32 | Why? |
| Cardiac Pacing, Artificial | 2 | 2019 | 160 | 0.32 | Why? |
| Blood Coagulation | 2 | 2017 | 2768 | 0.32 | Why? |
| Dabigatran | 2 | 2019 | 204 | 0.32 | Why? |
| Kidney Failure, Chronic | 4 | 2019 | 3222 | 0.32 | Why? |
| Diabetes Mellitus | 6 | 2021 | 8207 | 0.31 | Why? |
| Antithrombins | 3 | 2019 | 353 | 0.31 | Why? |
| Anti-Arrhythmia Agents | 3 | 2019 | 325 | 0.31 | Why? |
| Postoperative Complications | 7 | 2019 | 5861 | 0.30 | Why? |
| Humans | 160 | 2022 | 930598 | 0.30 | Why? |
| Comorbidity | 29 | 2021 | 34796 | 0.30 | Why? |
| Heart Valve Diseases | 3 | 2019 | 355 | 0.30 | Why? |
| Coronary Angiography | 4 | 2019 | 2275 | 0.29 | Why? |
| Thrombolytic Therapy | 1 | 2017 | 2218 | 0.29 | Why? |
| Venous Thromboembolism | 6 | 2019 | 4273 | 0.28 | Why? |
| Factor Xa Inhibitors | 3 | 2019 | 490 | 0.28 | Why? |
| Coronary Artery Disease | 6 | 2019 | 2570 | 0.28 | Why? |
| Aspirin | 5 | 2019 | 1043 | 0.27 | Why? |
| Platelet Aggregation Inhibitors | 7 | 2019 | 1671 | 0.26 | Why? |
| Retrospective Studies | 46 | 2021 | 105322 | 0.26 | Why? |
| Administration, Oral | 7 | 2018 | 2340 | 0.25 | Why? |
| Secondary Prevention | 3 | 2019 | 762 | 0.25 | Why? |
| Venous Thrombosis | 2 | 2019 | 2739 | 0.24 | Why? |
| Renal Replacement Therapy | 1 | 2012 | 1530 | 0.24 | Why? |
| Pyridones | 2 | 2018 | 738 | 0.24 | Why? |
| Cardiotonic Agents | 2 | 2018 | 418 | 0.24 | Why? |
| International Normalized Ratio | 3 | 2019 | 300 | 0.24 | Why? |
| Pulmonary Disease, Chronic Obstructive | 5 | 2021 | 3832 | 0.23 | Why? |
| Scleroderma, Systemic | 2 | 2019 | 583 | 0.23 | Why? |
| Staphylococcus aureus | 2 | 2019 | 844 | 0.23 | Why? |
| Hidradenitis Suppurativa | 2 | 2017 | 309 | 0.23 | Why? |
| Drug Prescriptions | 4 | 2020 | 1062 | 0.23 | Why? |
| Metoprolol | 2 | 2018 | 42 | 0.22 | Why? |
| Nifedipine | 1 | 2020 | 27 | 0.22 | Why? |
| Calcium Channel Blockers | 3 | 2020 | 367 | 0.22 | Why? |
| Primary Prevention | 2 | 2019 | 778 | 0.22 | Why? |
| Adaptation, Psychological | 1 | 2019 | 4996 | 0.22 | Why? |
| Amlodipine | 1 | 2020 | 45 | 0.22 | Why? |
| Staphylococcal Infections | 3 | 2019 | 1099 | 0.21 | Why? |
| Stroke Volume | 3 | 2020 | 2153 | 0.21 | Why? |
| Ventricular Dysfunction, Left | 2 | 2019 | 993 | 0.21 | Why? |
| Aortic Valve Stenosis | 2 | 2018 | 741 | 0.20 | Why? |
| Tendon Injuries | 1 | 2019 | 27 | 0.20 | Why? |
| Hospitalization | 19 | 2021 | 54280 | 0.20 | Why? |
| Achilles Tendon | 1 | 2019 | 26 | 0.20 | Why? |
| Anthropology, Cultural | 1 | 2019 | 69 | 0.20 | Why? |
| Adult | 58 | 2021 | 244371 | 0.20 | Why? |
| Amiodarone | 2 | 2019 | 110 | 0.20 | Why? |
| Ventricular Pressure | 1 | 2018 | 25 | 0.19 | Why? |
| Penicillin V | 1 | 2018 | 10 | 0.19 | Why? |
| Mitral Valve | 2 | 2019 | 342 | 0.19 | Why? |
| Epirubicin | 1 | 2018 | 21 | 0.19 | Why? |
| Hospital Mortality | 4 | 2021 | 22087 | 0.19 | Why? |
| Logistic Models | 13 | 2019 | 9089 | 0.19 | Why? |
| Thymectomy | 1 | 2018 | 26 | 0.19 | Why? |
| Prevalence | 14 | 2020 | 25773 | 0.19 | Why? |
| Odds Ratio | 10 | 2018 | 5861 | 0.18 | Why? |
| Adrenergic beta-1 Receptor Agonists | 1 | 2017 | 6 | 0.18 | Why? |
| Cause of Death | 11 | 2019 | 4823 | 0.18 | Why? |
| Drug Substitution | 2 | 2019 | 385 | 0.18 | Why? |
| Scleroderma, Localized | 1 | 2018 | 25 | 0.18 | Why? |
| Atrial Function, Left | 1 | 2019 | 82 | 0.18 | Why? |
| Propanolamines | 1 | 2018 | 47 | 0.18 | Why? |
| Aortic Valve | 3 | 2019 | 664 | 0.18 | Why? |
| Heart Diseases | 3 | 2020 | 3503 | 0.18 | Why? |
| Intermediate Filament Proteins | 1 | 2017 | 9 | 0.18 | Why? |
| Neonatal Sepsis | 1 | 2018 | 69 | 0.17 | Why? |
| Renal Insufficiency, Chronic | 3 | 2021 | 2654 | 0.17 | Why? |
| Paternal Exposure | 1 | 2017 | 13 | 0.17 | Why? |
| Gastroplasty | 1 | 2017 | 20 | 0.17 | Why? |
| Hyperprolactinemia | 1 | 2017 | 19 | 0.17 | Why? |
| Fetal Membranes, Premature Rupture | 1 | 2018 | 122 | 0.17 | Why? |
| Systole | 1 | 2018 | 252 | 0.17 | Why? |
| Neoplasms | 8 | 2019 | 17251 | 0.17 | Why? |
| Employment | 3 | 2018 | 1754 | 0.17 | Why? |
| Pyrazoles | 2 | 2018 | 1791 | 0.17 | Why? |
| Naproxen | 1 | 2017 | 47 | 0.17 | Why? |
| Proton Pump Inhibitors | 2 | 2019 | 377 | 0.17 | Why? |
| Sulfones | 1 | 2017 | 66 | 0.17 | Why? |
| Retinal Artery Occlusion | 1 | 2018 | 57 | 0.17 | Why? |
| Celecoxib | 1 | 2017 | 49 | 0.17 | Why? |
| Institutionalization | 1 | 2017 | 81 | 0.17 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 2 | 2017 | 1261 | 0.17 | Why? |
| Osteoporotic Fractures | 1 | 2019 | 175 | 0.17 | Why? |
| Accidents, Occupational | 1 | 2017 | 46 | 0.17 | Why? |
| Myocardial Revascularization | 1 | 2019 | 267 | 0.17 | Why? |
| Lactones | 1 | 2017 | 62 | 0.16 | Why? |
| Carbazoles | 1 | 2018 | 120 | 0.16 | Why? |
| Torsades de Pointes | 1 | 2019 | 229 | 0.16 | Why? |
| Keratoconus | 1 | 2017 | 42 | 0.16 | Why? |
| Cyclooxygenase 2 Inhibitors | 1 | 2016 | 48 | 0.16 | Why? |
| Aortic Valve Insufficiency | 1 | 2018 | 136 | 0.16 | Why? |
| Gallstones | 1 | 2017 | 64 | 0.16 | Why? |
| Keratosis, Actinic | 1 | 2017 | 54 | 0.16 | Why? |
| Adolescent | 25 | 2020 | 86841 | 0.16 | Why? |
| Retirement | 1 | 2017 | 157 | 0.16 | Why? |
| Lupus Erythematosus, Systemic | 2 | 2018 | 1380 | 0.16 | Why? |
| Survival Rate | 10 | 2019 | 9206 | 0.16 | Why? |
| Patient Readmission | 4 | 2019 | 1543 | 0.16 | Why? |
| Craniocerebral Trauma | 1 | 2018 | 160 | 0.16 | Why? |
| Osteoarthritis | 1 | 2019 | 205 | 0.16 | Why? |
| Fibrinolytic Agents | 2 | 2018 | 1702 | 0.16 | Why? |
| Heart Atria | 1 | 2019 | 267 | 0.16 | Why? |
| Keratitis | 1 | 2017 | 102 | 0.16 | Why? |
| Diabetic Angiopathies | 1 | 2018 | 146 | 0.16 | Why? |
| Rosacea | 1 | 2017 | 57 | 0.16 | Why? |
| Anti-Anxiety Agents | 1 | 2017 | 139 | 0.15 | Why? |
| Mental Disorders | 4 | 2021 | 6742 | 0.15 | Why? |
| History, 21st Century | 3 | 2018 | 1849 | 0.15 | Why? |
| Ischemic Attack, Transient | 1 | 2020 | 439 | 0.15 | Why? |
| Prognosis | 15 | 2020 | 32490 | 0.15 | Why? |
| Retinal Vein Occlusion | 1 | 2018 | 129 | 0.15 | Why? |
| Treatment Outcome | 20 | 2019 | 51732 | 0.15 | Why? |
| Acute Kidney Injury | 1 | 2016 | 5762 | 0.15 | Why? |
| Acute Coronary Syndrome | 2 | 2020 | 2107 | 0.15 | Why? |
| Recurrence | 7 | 2018 | 3675 | 0.15 | Why? |
| Arrhythmias, Cardiac | 3 | 2019 | 2510 | 0.15 | Why? |
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2020 | 1510 | 0.15 | Why? |
| Pedigree | 1 | 2016 | 502 | 0.15 | Why? |
| Absenteeism | 1 | 2017 | 287 | 0.15 | Why? |
| Hyperkalemia | 1 | 2017 | 140 | 0.15 | Why? |
| Automobile Driving | 1 | 2018 | 222 | 0.15 | Why? |
| Antidepressive Agents | 2 | 2019 | 509 | 0.15 | Why? |
| Bradycardia | 1 | 2019 | 292 | 0.15 | Why? |
| Congenital Abnormalities | 1 | 2017 | 170 | 0.15 | Why? |
| Erectile Dysfunction | 1 | 2017 | 141 | 0.14 | Why? |
| Intraoperative Complications | 1 | 2017 | 221 | 0.14 | Why? |
| Gastric Bypass | 1 | 2017 | 152 | 0.14 | Why? |
| Multivariate Analysis | 7 | 2019 | 5440 | 0.14 | Why? |
| Mortality | 4 | 2019 | 7132 | 0.14 | Why? |
| Young Adult | 25 | 2020 | 93724 | 0.14 | Why? |
| Emergency Medical Services | 7 | 2019 | 3557 | 0.14 | Why? |
| Macrolides | 1 | 2018 | 369 | 0.14 | Why? |
| History, 20th Century | 2 | 2018 | 1282 | 0.14 | Why? |
| Hypokalemia | 1 | 2017 | 195 | 0.14 | Why? |
| Communicable Disease Control | 5 | 2022 | 29620 | 0.14 | Why? |
| Potassium | 1 | 2017 | 325 | 0.13 | Why? |
| Cataract | 1 | 2017 | 186 | 0.13 | Why? |
| Nursing Homes | 4 | 2019 | 4155 | 0.13 | Why? |
| Dose-Response Relationship, Drug | 3 | 2020 | 3776 | 0.13 | Why? |
| Accidental Falls | 1 | 2018 | 448 | 0.13 | Why? |
| Epidemiologic Methods | 1 | 2017 | 392 | 0.13 | Why? |
| Age Factors | 11 | 2019 | 21039 | 0.13 | Why? |
| Prosthesis-Related Infections | 1 | 2017 | 302 | 0.13 | Why? |
| Percutaneous Coronary Intervention | 3 | 2018 | 3646 | 0.13 | Why? |
| Renal Insufficiency | 2 | 2019 | 810 | 0.13 | Why? |
| Catheter Ablation | 1 | 2018 | 438 | 0.13 | Why? |
| Conjunctivitis | 1 | 2017 | 318 | 0.13 | Why? |
| Diabetes, Gestational | 1 | 2018 | 426 | 0.12 | Why? |
| Ventricular Function, Left | 2 | 2020 | 1555 | 0.12 | Why? |
| Gastrointestinal Hemorrhage | 1 | 2019 | 669 | 0.12 | Why? |
| Patient Reported Outcome Measures | 1 | 2018 | 912 | 0.12 | Why? |
| Mandatory Programs | 1 | 2017 | 291 | 0.12 | Why? |
| Propensity Score | 2 | 2019 | 2690 | 0.12 | Why? |
| Heart Rate | 2 | 2019 | 1527 | 0.12 | Why? |
| Anemia | 1 | 2019 | 789 | 0.12 | Why? |
| Medical Record Linkage | 1 | 2012 | 58 | 0.12 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 6 | 2020 | 5277 | 0.12 | Why? |
| Thoracic Surgical Procedures | 1 | 2018 | 504 | 0.12 | Why? |
| Surgical Procedures, Operative | 2 | 2018 | 2662 | 0.12 | Why? |
| Echocardiography | 3 | 2020 | 3661 | 0.12 | Why? |
| Arthroplasty, Replacement, Knee | 1 | 2017 | 363 | 0.11 | Why? |
| Arthroplasty, Replacement, Hip | 1 | 2017 | 403 | 0.11 | Why? |
| Interpersonal Relations | 1 | 2019 | 926 | 0.11 | Why? |
| Immunization Schedule | 1 | 2019 | 1305 | 0.11 | Why? |
| Cardiac Catheterization | 1 | 2018 | 882 | 0.11 | Why? |
| Unemployment | 1 | 2017 | 702 | 0.11 | Why? |
| Survival Analysis | 3 | 2019 | 7592 | 0.11 | Why? |
| Heart Ventricles | 1 | 2019 | 1139 | 0.11 | Why? |
| Hip Fractures | 1 | 2018 | 667 | 0.11 | Why? |
| Vasculitis | 1 | 2017 | 691 | 0.10 | Why? |
| Exercise Test | 1 | 2017 | 911 | 0.10 | Why? |
| Breast Neoplasms | 2 | 2019 | 3633 | 0.10 | Why? |
| Data Mining | 1 | 2016 | 767 | 0.10 | Why? |
| Infant | 8 | 2019 | 30274 | 0.10 | Why? |
| Child, Preschool | 9 | 2019 | 36283 | 0.10 | Why? |
| Long QT Syndrome | 1 | 2019 | 1047 | 0.10 | Why? |
| Predictive Value of Tests | 6 | 2020 | 9537 | 0.10 | Why? |
| Guideline Adherence | 2 | 2019 | 2309 | 0.09 | Why? |
| Patient Discharge | 5 | 2021 | 5696 | 0.09 | Why? |
| Depression | 5 | 2018 | 14116 | 0.09 | Why? |
| Mothers | 1 | 2018 | 1624 | 0.09 | Why? |
| Bacteremia | 1 | 2019 | 1372 | 0.09 | Why? |
| Homes for the Aged | 1 | 2018 | 1071 | 0.09 | Why? |
| Teaching | 1 | 2017 | 1208 | 0.09 | Why? |
| Crohn Disease | 1 | 2017 | 959 | 0.09 | Why? |
| Disease Susceptibility | 1 | 2021 | 4002 | 0.08 | Why? |
| Age Distribution | 4 | 2017 | 3567 | 0.08 | Why? |
| Colitis, Ulcerative | 1 | 2017 | 1037 | 0.08 | Why? |
| Lower Extremity | 1 | 2012 | 593 | 0.08 | Why? |
| Qualitative Research | 1 | 2019 | 4337 | 0.08 | Why? |
| Sex Distribution | 3 | 2020 | 2083 | 0.08 | Why? |
| Computed Tomography Angiography | 1 | 2017 | 2153 | 0.08 | Why? |
| Severity of Illness Index | 5 | 2021 | 48226 | 0.08 | Why? |
| Angiotensin Receptor Antagonists | 2 | 2020 | 3892 | 0.08 | Why? |
| Peripheral Arterial Disease | 1 | 2012 | 471 | 0.08 | Why? |
| Diuretics | 2 | 2019 | 326 | 0.08 | Why? |
| Electrocardiography | 2 | 2018 | 3957 | 0.08 | Why? |
| Diabetes Complications | 1 | 2018 | 2358 | 0.08 | Why? |
| Obesity, Morbid | 1 | 2017 | 1340 | 0.08 | Why? |
| Cardiac Resynchronization Therapy | 2 | 2019 | 191 | 0.08 | Why? |
| Drug Therapy | 1 | 2008 | 280 | 0.07 | Why? |
| Blood Pressure | 1 | 2016 | 2198 | 0.07 | Why? |
| Wounds and Injuries | 1 | 2018 | 1708 | 0.07 | Why? |
| Risk | 4 | 2018 | 5288 | 0.07 | Why? |
| Child | 9 | 2021 | 70012 | 0.07 | Why? |
| Patient Admission | 2 | 2019 | 5250 | 0.07 | Why? |
| Kaplan-Meier Estimate | 3 | 2019 | 4260 | 0.07 | Why? |
| Evidence-Based Medicine | 1 | 2017 | 3228 | 0.07 | Why? |
| Suicide | 1 | 2017 | 1500 | 0.07 | Why? |
| Arthritis, Rheumatoid | 1 | 2018 | 2043 | 0.07 | Why? |
| Autoimmune Diseases | 1 | 2017 | 1996 | 0.07 | Why? |
| Quarantine | 2 | 2021 | 18418 | 0.06 | Why? |
| Kidney | 1 | 2017 | 3648 | 0.06 | Why? |
| Forecasting | 1 | 2018 | 4492 | 0.06 | Why? |
| Glomerular Filtration Rate | 2 | 2021 | 1262 | 0.06 | Why? |
| Communicable Diseases | 1 | 2018 | 2148 | 0.06 | Why? |
| Educational Status | 2 | 2021 | 1451 | 0.06 | Why? |
| Quality of Life | 3 | 2018 | 9820 | 0.06 | Why? |
| Influenza Vaccines | 1 | 2019 | 2941 | 0.06 | Why? |
| Asthma | 1 | 2021 | 4383 | 0.06 | Why? |
| Biological Products | 1 | 2017 | 2331 | 0.06 | Why? |
| Pandemics | 12 | 2021 | 389249 | 0.06 | Why? |
| Healthcare Disparities | 1 | 2019 | 3893 | 0.06 | Why? |
| Netherlands | 2 | 2020 | 3533 | 0.06 | Why? |
| Cross-Sectional Studies | 9 | 2018 | 53120 | 0.06 | Why? |
| Adrenal Cortex Hormones | 1 | 2018 | 6537 | 0.05 | Why? |
| Schools | 1 | 2017 | 4187 | 0.05 | Why? |
| Occupational Health | 1 | 2017 | 3965 | 0.05 | Why? |
| Kidney Diseases | 1 | 2012 | 1434 | 0.05 | Why? |
| Fracture Healing | 1 | 2019 | 37 | 0.05 | Why? |
| Machine Learning | 1 | 2016 | 4395 | 0.05 | Why? |
| Epidemics | 1 | 2020 | 6407 | 0.05 | Why? |
| Calcium Signaling | 1 | 2020 | 133 | 0.05 | Why? |
| Drug Therapy, Combination | 3 | 2018 | 7268 | 0.05 | Why? |
| Practice Guidelines as Topic | 3 | 2019 | 15421 | 0.05 | Why? |
| Poisson Distribution | 1 | 2020 | 348 | 0.05 | Why? |
| Anti-Bacterial Agents | 2 | 2019 | 10083 | 0.05 | Why? |
| Primary Health Care | 1 | 2017 | 4839 | 0.05 | Why? |
| Hypertension | 2 | 2020 | 8895 | 0.05 | Why? |
| Action Potentials | 1 | 2020 | 368 | 0.05 | Why? |
| Nebivolol | 1 | 2017 | 12 | 0.05 | Why? |
| Immunosuppressive Agents | 1 | 2017 | 6331 | 0.05 | Why? |
| Pensions | 1 | 2017 | 11 | 0.05 | Why? |
| Biomechanical Phenomena | 1 | 2019 | 291 | 0.04 | Why? |
| PUVA Therapy | 1 | 2017 | 11 | 0.04 | Why? |
| Alcohol-Related Disorders | 1 | 2018 | 84 | 0.04 | Why? |
| Bisoprolol | 1 | 2017 | 65 | 0.04 | Why? |
| Spironolactone | 1 | 2019 | 114 | 0.04 | Why? |
| Confidence Intervals | 1 | 2020 | 744 | 0.04 | Why? |
| Death Certificates | 1 | 2019 | 130 | 0.04 | Why? |
| Administration, Topical | 1 | 2018 | 272 | 0.04 | Why? |
| Mineralocorticoid Receptor Antagonists | 1 | 2019 | 203 | 0.04 | Why? |
| Sex Factors | 3 | 2019 | 11014 | 0.04 | Why? |
| Antibiotics, Antineoplastic | 1 | 2018 | 128 | 0.04 | Why? |
| Kidney Transplantation | 1 | 2017 | 5397 | 0.04 | Why? |
| Reproducibility of Results | 3 | 2019 | 11304 | 0.04 | Why? |
| Cardiac Resynchronization Therapy Devices | 1 | 2017 | 64 | 0.04 | Why? |
| Administrative Claims, Healthcare | 1 | 2016 | 124 | 0.04 | Why? |
| Cardiomyopathy, Hypertrophic | 1 | 2019 | 193 | 0.04 | Why? |
| Arteriovenous Shunt, Surgical | 1 | 2017 | 93 | 0.04 | Why? |
| Mood Disorders | 1 | 2021 | 431 | 0.04 | Why? |
| Acute Disease | 2 | 2020 | 6029 | 0.04 | Why? |
| Diabetes Mellitus, Type 2 | 1 | 2018 | 6166 | 0.04 | Why? |
| Ultraviolet Therapy | 1 | 2018 | 138 | 0.04 | Why? |
| Infant, Newborn | 4 | 2018 | 23105 | 0.04 | Why? |
| Drug Utilization Review | 1 | 2017 | 72 | 0.04 | Why? |
| Mutation | 1 | 2017 | 12376 | 0.04 | Why? |
| Age of Onset | 1 | 2018 | 557 | 0.04 | Why? |
| Antihypertensive Agents | 2 | 2020 | 1962 | 0.04 | Why? |
| Obesity | 1 | 2017 | 7388 | 0.04 | Why? |
| Prosthesis Implantation | 1 | 2018 | 261 | 0.04 | Why? |
| Thrombosis | 1 | 2018 | 7504 | 0.04 | Why? |
| Pilot Projects | 2 | 2018 | 5182 | 0.04 | Why? |
| Pneumonia, Viral | 6 | 2021 | 243684 | 0.04 | Why? |
| Induced Pluripotent Stem Cells | 1 | 2020 | 584 | 0.04 | Why? |
| Central Venous Catheters | 1 | 2017 | 188 | 0.04 | Why? |
| Knee Joint | 1 | 2017 | 194 | 0.04 | Why? |
| Intention to Treat Analysis | 1 | 2017 | 673 | 0.04 | Why? |
| Device Removal | 1 | 2017 | 221 | 0.04 | Why? |
| Coronavirus Infections | 5 | 2020 | 253789 | 0.03 | Why? |
| Cross-Over Studies | 1 | 2018 | 867 | 0.03 | Why? |
| Digestive System Diseases | 1 | 2019 | 378 | 0.03 | Why? |
| Myocytes, Cardiac | 1 | 2020 | 804 | 0.03 | Why? |
| Influenza, Human | 1 | 2019 | 10779 | 0.03 | Why? |
| Intensive Care Units | 1 | 2020 | 29594 | 0.03 | Why? |
| Polypharmacy | 1 | 2016 | 347 | 0.03 | Why? |
| Causality | 1 | 2017 | 857 | 0.03 | Why? |
| Heart Valve Prosthesis | 1 | 2019 | 533 | 0.03 | Why? |
| Emergency Service, Hospital | 1 | 2018 | 14232 | 0.03 | Why? |
| Adverse Drug Reaction Reporting Systems | 1 | 2018 | 694 | 0.03 | Why? |
| Disease-Free Survival | 1 | 2018 | 1654 | 0.03 | Why? |
| Protective Factors | 1 | 2019 | 1720 | 0.03 | Why? |
| Bipolar Disorder | 1 | 2021 | 744 | 0.03 | Why? |
| Databases, Factual | 2 | 2018 | 6248 | 0.03 | Why? |
| Troponin | 1 | 2018 | 1058 | 0.03 | Why? |
| Biological Therapy | 1 | 2017 | 456 | 0.03 | Why? |
| Cardiovascular Agents | 1 | 2018 | 663 | 0.03 | Why? |
| Psychotropic Drugs | 1 | 2017 | 396 | 0.03 | Why? |
| Radiopharmaceuticals | 1 | 2017 | 763 | 0.03 | Why? |
| Socioeconomic Factors | 2 | 2021 | 8495 | 0.03 | Why? |
| Peritoneal Dialysis | 1 | 2017 | 498 | 0.03 | Why? |
| Europe | 2 | 2019 | 12702 | 0.03 | Why? |
| Anxiety | 1 | 2017 | 17311 | 0.03 | Why? |
| Information Storage and Retrieval | 1 | 2017 | 644 | 0.03 | Why? |
| Aftercare | 1 | 2021 | 1637 | 0.03 | Why? |
| Creatinine | 1 | 2017 | 1443 | 0.03 | Why? |
| Volunteers | 1 | 2017 | 601 | 0.03 | Why? |
| Dermatologic Agents | 1 | 2017 | 489 | 0.03 | Why? |
| Cerebrovascular Disorders | 1 | 2019 | 1040 | 0.03 | Why? |
| Respiratory Tract Diseases | 1 | 2019 | 1061 | 0.03 | Why? |
| Drug Monitoring | 1 | 2019 | 1408 | 0.03 | Why? |
| Schizophrenia | 1 | 2021 | 1018 | 0.03 | Why? |
| Pain | 1 | 2019 | 1084 | 0.03 | Why? |
| Sweden | 1 | 2017 | 1969 | 0.03 | Why? |
| Betacoronavirus | 5 | 2020 | 204454 | 0.03 | Why? |
| Activities of Daily Living | 1 | 2018 | 1530 | 0.02 | Why? |
| Fluorodeoxyglucose F18 | 1 | 2017 | 1153 | 0.02 | Why? |
| Length of Stay | 2 | 2018 | 11042 | 0.02 | Why? |
| Cells, Cultured | 1 | 2020 | 5835 | 0.02 | Why? |
| Drug Interactions | 1 | 2016 | 1653 | 0.02 | Why? |
| Social Class | 1 | 2017 | 1360 | 0.02 | Why? |
| Terminal Care | 1 | 2019 | 928 | 0.02 | Why? |
| Practice Patterns, Physicians' | 2 | 2018 | 4927 | 0.02 | Why? |
| Sotalol | 1 | 2008 | 9 | 0.02 | Why? |
| Antifungal Agents | 1 | 2019 | 1828 | 0.02 | Why? |
| Patient Education as Topic | 1 | 2018 | 1476 | 0.02 | Why? |
| Public Policy | 1 | 2021 | 1894 | 0.02 | Why? |
| Program Evaluation | 1 | 2017 | 1929 | 0.02 | Why? |
| Digoxin | 1 | 2008 | 68 | 0.02 | Why? |
| Heart Arrest | 1 | 2018 | 1239 | 0.02 | Why? |
| Longitudinal Studies | 2 | 2017 | 9893 | 0.02 | Why? |
| Patient Care Management | 1 | 2019 | 1514 | 0.02 | Why? |
| Autopsy | 1 | 2019 | 3495 | 0.02 | Why? |
| Positron Emission Tomography Computed Tomography | 1 | 2017 | 1458 | 0.02 | Why? |
| Coronary Disease | 1 | 2012 | 645 | 0.02 | Why? |
| Health Education | 1 | 2017 | 1539 | 0.02 | Why? |
| Body Mass Index | 1 | 2018 | 4306 | 0.02 | Why? |
| Health Status | 1 | 2019 | 3259 | 0.02 | Why? |
| Canada | 1 | 2018 | 6018 | 0.02 | Why? |
| Survivors | 1 | 2017 | 2619 | 0.02 | Why? |
| Prospective Studies | 2 | 2020 | 43301 | 0.02 | Why? |
| Cardiology | 1 | 2019 | 2873 | 0.02 | Why? |
| Smoking | 1 | 2017 | 3358 | 0.02 | Why? |
| Chronic Disease | 1 | 2017 | 5139 | 0.02 | Why? |
| Antirheumatic Agents | 1 | 2017 | 3023 | 0.01 | Why? |
| Genetic Predisposition to Disease | 1 | 2017 | 4027 | 0.01 | Why? |
| Hospitals | 1 | 2021 | 11793 | 0.01 | Why? |
| Mental Health Services | 1 | 2018 | 3007 | 0.01 | Why? |
| Time-to-Treatment | 1 | 2018 | 5883 | 0.01 | Why? |
| T-Lymphocytes | 1 | 2018 | 6670 | 0.01 | Why? |
| United States | 2 | 2018 | 46150 | 0.01 | Why? |
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2021 | 9706 | 0.01 | Why? |
| Biomarkers | 1 | 2020 | 23361 | 0.01 | Why? |
| Pregnancy | 1 | 2018 | 23879 | 0.01 | Why? |
| Delivery of Health Care | 1 | 2021 | 15909 | 0.01 | Why? |
| Health Services Accessibility | 1 | 2017 | 10697 | 0.01 | Why? |
| Italy | 1 | 2018 | 38444 | 0.01 | Why? |
| Global Health | 1 | 2017 | 13911 | 0.01 | Why? |
| China | 1 | 2020 | 50654 | 0.01 | Why? |
| Health Personnel | 1 | 2021 | 29646 | 0.01 | Why? |